Still, a few of the hardest hit rated as Criterion "buys" over the past 12 months. We'll take the opportunity to revisit Solagran (SLA, $1.44) and Jumbuck Entertainment (JMB, 60c).
Embarrassingly, we backed Solagran as a speculative buy at $1.44 last May, lured by a rollicking yarn about Solagran's Russian-oriented work in turning pine needles into pharmaceuticals.
At the time, several well-meaning acquaintances inquired about your columnist's sanity, but Solagran also has loyal fans. We'll side with the naysayers and avoid the stock.
